Rafal Swierzewski

President of Board

Back to Speakers

Rafal Swierzewski has been involved in patient advocacy for ten years as both a scientist and rare cancer survivor. He earned his PhD in 2006 in chemistry by examining physical and chemical properties of model macromolecules (incl. new chemotherapy compounds) in cellular environment. From 2013 to 2016 he served as Board Member of the European Cancer Patient Coalition (ECPC). Currently, he continue his activity, representing ECPC in Patients’ and Consumers’ Working Party within the European Medicines Agency (EMA). Through the EMA, he is involved in various projects, such as Adaptive Pathways, IMI- ADVANCE (Scientific Advisory Board member) and IMI-WEBRADR. Rafal also represents patients’ interests in the Stakeholders Group for European Union’s clinical trial portal and database, created by EMA to construct new system for implementing European regulations on clinical trials and clinical data. Rafal is also a member of Technical Anonymization Group (TAG) of the EMA, which continue the work undertaken during the development and finalisation of the external guidance on the anonymization of clinical reports for publication. From March 2018 he is President of the Board of Foundation for Patients with Rare Diseases “COCARDA”, an innovative patients’ driven research organization established in Poland.